RA
KURA icon

Rise Advisors’s Kura Oncology KURA Stock Holding History

Rise Advisors’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-531
Closed -$4.63K – 1538
2024
Q4 		$4.63K Hold
531
– – ﹤0.01% 1054
2024
Q3 		$10.4K Hold
531
– – 0.01% 1003
2024
Q2 		$10.9K Hold
531
– – 0.01% 981
2024
Q1 		$11.3K Buy
+531
New +$10.3K 0.01% 1022

Other funds holding KURA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Rise Advisors's KURA Position: Q1 2025 in Review

Rise Advisors sold out of Kura Oncology (KURA) in Q1 2025, closing a stake of 531 shares — an estimated $4.63K sold.

Rise Advisors first reported a position in KURA in Q1 2024 and held it in 4 quarters. The position peaked at $11.3K in Q1 2024. 183 funds tracked by Wall St. Rank hold KURA as of Q1 2025.

  • Rise Advisors reported no remaining Kura Oncology position as of Q1 2025 after selling out during the quarter.
  • Rise Advisors sold 531 Kura Oncology shares in Q1 2025, an estimated $4.63K.
  • Rise Advisors first reported a position in Kura Oncology in Q1 2024 and held it in 4 quarters.
  • Rise Advisors's Kura Oncology position peaked at $11.3K in Q1 2024.
  • 183 funds tracked by Wall St. Rank held Kura Oncology as of Q1 2025.

Based on Rise Advisors's 13F filing for Q1 2025, filed 15 May 2025.